MARLBOROUGH, Mass.--(BUSINESS WIRE)--Advanced Cell Technology, Inc. (“ACT"; OTCBB: ACTCD), a leader in the field of regenerative medicine, announced today the addition of five leading scientists to its new Scientific Advisory Board. The Board will be chaired by Robert Langer, ScD, David H. Koch Institute Professor at MIT and member of ACT’s Board of Directors.
“We are honored to welcome such esteemed colleagues to our new Scientific Advisory Board,” said Robert Lanza, MD, Chief Scientific Officer at ACT, “The Company will benefit greatly from their new perspectives and diversity of experience and together they bring extensive expertise in cell biology, clinical translation, and the broader field of regenerative medicine. Together with Dr. Langer, the new Board spans the continuum from laboratory and translational research to drugs and biologics development through clinical trials. Dr. Lanza added “ACT is at the forefront of regenerative medicine and plans to initiate phase 2 clinical trials for the treatment of Stargardt’s macular degeneration (SMD) and age-related macular degeneration (AMD). The Company has made substantial progress in these areas and as advisors, the SAB will be critical in harnessing creativity with scientific rigor to help steer the Company in its pursuit of discovery and development of novel therapies for patients in need.”
Help employers find you! Check out all the jobs and post your resume.
